NIC-0102 is an orally active proteasome inhibitor (pIC50 = 7.55) that specifically inhibits NLRP3 inflammasome activation; it exhibits potent anti-inflammatory effects in a DSS-induced murine model of ulcerative colitis and suppresses pro-IL-1β production.